Drug Profile
Smallpox subunit vaccine - Regalen/National Center of Biotechnology
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator CNB; Regalen
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Smallpox
Most Recent Events
- 13 Sep 2005 Galencia Pharmaceuticals is now called Regalen Inc
- 28 Sep 2004 Galenica Pharmaceuticals has been acquired by Australian Cancer Technology
- 14 Feb 2003 Preclinical trials in Smallpox in Spain (unspecified route)